Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
Ultragenyx (NASDAQ: RARE) will participate in Bank of America’s 2026 Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) will participate in Bank of America’s 2026 Healthcare Conference. Company executives Howard Horn, CFO and EVP, and Joshua Higa, Chief of Staff and VP Investor Relations, will appear in a fireside on May 12, 2026 at 2:20 PM PT.
A live and archived webcast will be available on the company’s investor site at https://ir.ultragenyx.com/events-presentations.
Details
News Market Reaction – RARE
On May 7, the first trading day after this news, RARE closed 0.77% above the previous close.
Data tracked by StockTitan Argus for the May 7 session.
Key Figures
- Conference date
- May 12, 2026
- Date of Ultragenyx fireside participation at Bank of America’s 2026 Healthcare Conference
- Conference time
- 2:20 PM PT
- Scheduled time for the Bank of America 2026 Healthcare Conference fireside session
Historical Context
-
Announced date and time for Q1 2026 results conference call.
-
Reported RSU inducement awards to new non-executive officers under Nasdaq rules.
-
FDA acceptance of UX111 BLA resubmission with Priority Review and long-term data.
-
FDA cleared IND for UX016 with a planned Phase 1/2 study starting in 2H 2026.
-
Notice of application deadline for a class action lawsuit against the company.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America’s 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.